With multiple anti-CD20xCD3 bispecific antibodies hitting the market for B-cell non-Hodgkin lymphomas (NHL), it remains as yet unclear how to differentiate them in the clinic in terms of efficacy and safety, although they will likely play a complementary role to chimeric antigen receptor T-cell (CAR-T) cell therapies.
But the bigger question is how to move them from the hospital and cancer center setting where patients have typically...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?